RT @AmandaNizamMD
A very timely discussion about adjuvant treatment of high-risk resected RCC.
In light of the recent press release about CONTACT-03, will be interesting to discuss management of recurrent RCC on or after adjuvant therapy. #kcsm #OncTwitter @HemOncFellows https://twitter.com/tumorboardtues/status/1635335239823405057
RT @AmandaNizamMD
A very timely discussion about adjuvant treatment of high-risk resected RCC.
In light of the recent press release about CONTACT-03, will be interesting to discuss management of recurrent RCC on or after adjuvant therapy. #kcsm #OncTwitter @HemOncFellows https://twitter.com/tumorboardtues/status/1635335239823405057
@allenmichie I don't want to change my instance, but I will follow anyone I see on jazztodon.
I have been a jazz fan since 1975. Growing up in and around Philly was wonderful.
RT @_ShankarSiva@twitter.com
🧵1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol@twitter.com; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect@twitter.com for 50-day link: #radonc #kcsm https://www.sciencedirect.com/science/article/pii/S1470204522006568?dgcid=author
🐦🔗: https://twitter.com/_ShankarSiva/status/1592729843283955712
Excellent 5-yr data on patients receiving stereotactic ablative radiotherapy for primary kidney cancer!
RT @_ShankarSiva@twitter.com
🧵1/ Wide adoption of SABR for primary #kidneycancer is limited by long-term data. Online today @TheLancetOncol@twitter.com; 5-yr outcomes in 190 patients. 5% local failure rates, 95% cancer-specific survival. Thanks @ElsevierConnect@twitter.com for 50-day link: #radonc #kcsm https://www.sciencedirect.com/science/article/pii/S1470204522006568?dgcid=author
🐦🔗: https://twitter.com/_ShankarSiva/status/1592729843283955712